BioCardia (BCDA) CEO Peter Altman Buys $768 of Stock

BioCardia, Inc. (NasdaqCM: BCDA) saw insider activity as its President and CEO, Peter Altman, purchased 800 shares on June 18, 2026. The shares were bought at an average price of $0.96, amounting to a total transaction value of $768. This purchase was not made under a pre-planned trading program.

Insider Buying and Selling at BioCardia, Inc.

Peter Altman, BioCardia's President and CEO, has been actively buying shares. On June 18, 2026, he bought 800 shares at $0.96 each. Earlier, on June 17, he acquired 1,500 shares at $0.85 each, and on June 9, he purchased 5,000 shares at the same price. Altman also made purchases in May, acquiring shares at prices ranging from $0.92 to $0.95.

Other Institutional Activity in BioCardia

Institutions have also been adjusting their holdings in BioCardia. Vanguard Capital Management LLC opened a new position with 124,591 shares valued at approximately $150,755. Geode Capital Management, LLC increased its stake by 28,284 shares, bringing its total to 94,287 shares worth about $114,086, representing a 42.9% increase. Meanwhile, Citadel Advisors LLC reduced its holdings by 30,863 shares, ending with 63,384 shares valued at $76,695, marking a 32.7% decrease.

BioCardia, Inc. Stock Down 17.1%

Shares of BioCardia (NasdaqCM: BCDA) traded near $0.97 on Tuesday. The company has a market cap of approximately $14.4 million. BioCardia is not currently profitable, so it has no meaningful P/E ratio. The stock has a 52-week low of $0.78 and a high of $2.45. Its 50-day moving average is $1.03, and the 200-day moving average is $1.27. The company's current ratio stands at 0.41, with a quick ratio of 0.35, indicating some liquidity challenges.

Analysts Set New Price Targets

On June 9, 2026, HC Wainwright & Co. reiterated its buy rating on BioCardia with a price target of $25. The firm has consistently maintained a buy rating over the past few years. Currently, the consensus among analysts is a strong buy, with a mean price target of $15.50 based on two analyst opinions.

About BioCardia

BioCardia, Inc. is a clinical-stage regenerative medicine company based in Sunnyvale, California. It focuses on developing cellular and cell-derived therapies for cardiovascular and pulmonary diseases. Its lead product, CardiAMP, is in Phase III trials for treating ischemic heart failure. The company also offers CardiALLO, an allogeneic stem cell therapy in Phase II trials, and PulmALLO for acute respiratory distress syndrome. BioCardia operates with a small team of 17 employees under the leadership of Dr. Peter A. Altman.

Bottom Line

BioCardia's recent insider buying by CEO Peter Altman highlights his confidence in the company's future. Investors track such activity as it can signal management's belief in the company's prospects. However, it's important to remember that these transactions are disclosed after the fact and don't necessarily predict future stock performance.